Clinical Trial

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction followed by cisplatin-based chemoradiation. The primary outcome will be 3-year disease-free survival.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-08-05; most recent amendment 2024-01-03.
Status change: Not Yet Recruiting → Recruiting 2022-08-31
Trial Details
NCT Number NCT05492123
Lead Sponsor Hospital Israelita Albert Einstein
Collaborators: Bristol-Myers Squibb, Brava
Conditions Uterine Cervical Neoplasms
Enrollment 112 participants
Start Date 2022-08-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-01-05